Literature DB >> 15589452

Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients.

O Brocq, C Albert, C Roux, D Gerard, V Breuil, L Euller Ziegler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15589452     DOI： 10.1016/j.jbspin.2004.07.009

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  4 in total

1.  Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure.

Authors:  Cheryl Barnabe; Susan G Barr; Liam Martin
Journal:  Clin Rheumatol       Date:  2011-07-01       Impact factor: 2.980

2.  Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Authors:  Liisa M Virkki; Heikki Valleala; Yuya Takakubo; Jorma Vuotila; Heikki Relas; Riitta Komulainen; Riitta Koivuniemi; Urpo Yli-Kerttula; Markku Mali; Susanna Sihvonen; Maija-Liisa Krogerus; Eero Jukka; Satu Nyrhinen; Yrjö T Konttinen; Dan C Nordström
Journal:  Clin Rheumatol       Date:  2011-06-07       Impact factor: 2.980

3.  Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors.

Authors:  Regina Rendas-Baum; Gene V Wallenstein; Tamas Koncz; Mark Kosinski; Min Yang; John Bradley; Samuel H Zwillich
Journal:  Arthritis Res Ther       Date:  2011-02-16       Impact factor: 5.156

4.  An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.

Authors:  Arie E van der Bijl; Ferdinand C Breedveld; Christian E Antoni; Joachim R Kalden; Sonja Kary; Gerd R Burmester; Christina Beckmann; Kristina Unnebrink; Hartmut Kupper
Journal:  Clin Rheumatol       Date:  2008-03-19       Impact factor: 2.980
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.